{
    "nct_id": "NCT06515613",
    "official_title": "A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors",
    "inclusion_criteria": "* Subjects with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.\n* Subject with measurable disease per RECIST 1.1\n* ECOG 0, 1, or 2\n* Subjects with adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.\n* Prior treatment with CLDN-6 targeted therapy.\n* Concurrent participation in another investigational clinical trial.",
    "miscellaneous_criteria": ""
}